Intellectual Property India Publishes Patent Application for 'Anti-Fel D1 Antibody Formulations' Filed by Regeneron Pharmaceuticals, Inc.

MUMBAI, India, Oct. 11 -- Intellectual Property India has published a patent application (202517091674 A) filed by Regeneron Pharmaceuticals, Inc., Tarrytown, U.S.A., on Sept. 24, for 'anti-fel d1 antibody formulations.'

Inventor(s) include Chen, Hunter; Minocha, Shalini; Nandagiri, Ritwik; Sharma, Saurav; Tang, Xiaolin; and Tzul, Franco.

The application for the patent was published on Oct. 10, under issue no. 41/2025.

According to the abstract released by the Intellectual Property India: "The present disclosure provides pharmaceutical formulations comprising one or more antibodies or antigen-binding fragments thereof that bind to the cat allergen Fel d1. The formulations may contain, in addition to the anti-Fel d1 antibody, a buffer, a thermal stabilizer, a viscosity reducer, and a surfactant. In one aspect, co-formulations comprising two anti-Fel d1 antibodies are provided that have acceptable stability and optimal viscosity."

The patent application was internationally filed on Feb. 29, 2024, under International application No.PCT/US2024/017919.

Disclaimer: Curated by HT Syndication.